UBS analyst Lu Li maintained a Neutral rating on Myriad Genetics (MYGN) but significantly lowered the price target from $6 to $3.6. This indicates a more cautious outlook from the analyst regarding the company's future performance and valuation.
UBS analyst Lu Li reiterated a 'Neutral' rating on Myriad Genetics but made a substantial cut to the price target, moving it from $6 down to $3.6. This action suggests that the analyst sees less upside potential or increased downside risk for MYGN shares in the near to medium term. While the rating itself didn't change, the significant reduction in the price target is a negative signal for investors, implying a re-evaluation of the company's fundamentals or market conditions affecting its valuation. This could lead to short-term selling pressure on MYGN as investors adjust their expectations based on this analyst's revised outlook. The long-term implications depend on whether other analysts follow suit or if the company can demonstrate performance that contradicts this more conservative valuation.